What happened with ZTS today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Zoetis develops and manufactures products that help prevent, detect and treat disease in animals. Pet products generate most of its revenue: veterinary distributors buy from Zoetis and supply veterinarians, who typically sell to pet owners; veterinarians also buy directly from the company. Its substantial livestock business serves farmers and other producers, selling through veterinarians and distributors as well as directly to producers.
Revenue depends in part on leading product lines such as Simparica/Simparica Trio and Apoquel/Apoquel Chewable. A single U.S. veterinary distributor is its largest customer and accounts for a substantial share of sales. Zoetis must obtain the required local approvals before marketing new products and maintain approvals for existing ones. Some countries also restrict or ban particular antibacterial medicines for food-producing animals, limiting what its livestock business can sell.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Zoetis’s results hinge mainly on demand for pet treatments and competing product launches, including those from privately held major rival Boehringer Ingelheim Animal Health.
Elanco competes with Zoetis for veterinarians’ and livestock producers’ spending on parasite control, skin treatments, vaccines and other animal medicines. Watch Elanco’s new pet treatments for advantages in ease of use, effectiveness or cost that could put pressure on Zoetis’s sales or prices.
IDEXX and Zoetis both depend on pet owners’ spending on veterinary care, while competing to sell diagnostic tests and equipment to veterinarians. IDEXX’s Companion Animal Group results offer a read on demand for pet testing, relevant to Zoetis’s diagnostics business.
Merck’s Animal Health division competes directly with Zoetis by selling veterinary medicines and vaccines to veterinarians, distributors and animal producers. Watch that division’s sales rather than Merck’s overall results, which are dominated by human medicines.
Phibro Animal Health Corporation competes with Zoetis for livestock producers’ spending on animal medicines and vaccines, but also bought the medicated feed-additive portfolio Zoetis exited in October 2024. Separate sales from that acquired portfolio when using Phibro’s results to gauge demand for the livestock treatments Zoetis still sells.
ZOETIS INC. earningsThis company
About 70% of Zoetis’s revenue comes from companion-animal products, so this report will show whether sales to the pet-care market can offset weakness in livestock products.
Read companion-animal sales alongside livestock sales. Growth in pets with livestock sales stabilizing would show that Zoetis’s largest business is still expanding and the other major business is no longer dragging; slower pet sales with further livestock declines would point to pressure in both. Together, the figures show whether pet products can keep carrying Zoetis’s growth.
Elanco Animal Health Incorporated earningsELAN
Elanco’s report will show whether its new pet treatments are winning spending from veterinarians and pet owners, putting pressure on Zoetis’s much larger companion-animal business.
Look for sales and adoption of Elanco’s new pet treatments, and whether the company ties uptake to ease of use, effectiveness or cost. Growing sales alongside those advantages would suggest veterinarians and pet owners may shift toward Elanco, making it harder for Zoetis to defend pet-medicine sales or prices; limited uptake would point to less immediate pressure. The results will show whether Elanco is becoming a stronger competitor to Zoetis in pets.
